StockUS listing USCGENNASDAQHealthcareQuality Compounder

Compugen(CGEN) Stock Analysis | Healthcare

USD --+0.00%
Reward70High
Risk72High
75%Data
Strong 48% profit margin · Revenue growing 102% YoY
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 174.29M
Reward Ratingⓘ70 High reward assessment · 75% data coverage
Top 25% of stocksView factors
Risk Ratingⓘ72 High risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on CGEN to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Compugen?

, a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe.

AI Brief Pro

The brief on Compugen

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Compugen?

, a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti- PD-1/TIGIT bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 174.29M, and a P/E ratio of 4.8x.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Strong margins and consistent earnings support financial stability.
Risk
Moderate volatility with meaningful macro and earnings sensitivity.
Valuation
Currently trading below intrinsic value estimates, suggesting upside potential.

OpenBook Logo Analysis

Reward: High (70)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
Market Cap174.29M
P/E Ratio4.8421
Beta2.816
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
0
0
3-6months
11,875 shares
$5k
0
6-9months
934,125 shares
$89k
0
9-12months
0
0